UNITED STATES
                    SECURITIES AND EXCHANGE COMMISSION
                          Washington, D.C. 20549

                                FORM 12b-25

                        NOTIFICATION OF LATE FILING

(Check one):   [x] Form 10-K  [ ] Form 20-F   [ ] Form 11-K   [ ] Form 10-Q
               [ ] Form 10-D  [ ] Form N-SAR  [ ] Form N-CSR

               For Period Ended:    December 31, 2008
                                    _________________
               [ ] Transition report on Form 10-K
               [ ] Transition Report on Form 20-F
               [ ] Transition Report on Form 11-K
               [ ] Transition Report on Form 10-Q
               [ ] Transition Report on Form N-SAR

               For the Transition Period Ended: ___________________________

Nothing  in  this  form shall be construed to imply that the Commission has
verified any information contained herein.

If  the  notification  relates  to  a  portion of the filing checked above,
identify the Item(s) to which the notification relates:
___________________________________________________________________________

PART I - REGISTRANT INFORMATION

     IGENE BIOTECHNOLOGY, INC.
     ______________________________________________________________________
     Full Name of Registrant

     N/A
     ______________________________________________________________________
     Form Name if Applicable

     9110 Red Branch Road
     ______________________________________________________________________
     Address of Principal Executive Office (Street and Number)

     Columbia, Maryland  21045-2024
     ______________________________________________________________________
     City, State and Zip Code

PART II - RULES 12b-25(b) AND (c)

If  the  subject report could not be filed without unreasonable  effort  or
expense  and  the registrant seeks relief pursuant to Rule  12b-25(b),  the
following should be completed.  (Check box if appropriate)

     (a) The reason described in reasonable detail in Part III of this form
         could not  be  eliminated  without unreasonable effort or expense.
     (b) The subject  annual report, semi-annual  report, transition report
         on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or  Form  N-CSR, or
         portion thereof, will be filed on or before the fifteenth calendar
 [x]     day following the prescribed due date;  or  the  subject quarterly
         report or transition report on Form 10-Q  or  subject distribution
         report  on  Form  10-D, or portion  thereof,  will  be filed on or
         before the  fifth  calendar day following the prescribed due date;
         and
     (c) The  accountant's  statement  or  other  exhibit  required by Rule
         12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-
SAR, N-CSR, or the transition report or portion thereof, could not be filed
within the prescribed time period.

The  Registrant  encountered  technical  difficulties  when  attempting  to
electronically  file  its annual report on Form 10-K  for  the  year  ended
December  31,  2008  on the afternoon of March 31, 2009.   These  technical
difficulties caused the report to be filed at 5:43 pm on March 31, 2009.

PART IV - OTHER INFORMATION

(1)  Name  and  telephone number of person to  contact in  regard  to  this
     notification

     Edward J. Weisberger                 410                997-2599
     _____________________________    ___________      ____________________
                (Name)                (Area Code)       (Telephone Number)

(2)  Have  all  other  periodic reports required under Section 13 or  15(d)
     of the Securities Exchange Act of 1934 or Section 30 of the Investment
     Company Act of 1940 during the preceding 12 months or for such shorter
     period that the registrant was required to file  such  report(s)  been
     filed?   If answer is no, identify report(s).   Yes  [x]   No  [ ]

     ______________________________________________________________________

(3)  Is  it  anticipated   that  any  significant  change  in   results  of
     operations from the corresponding period for the last fiscal year will
     be reflected by the earnings statements to be included in the  subject
     report or portion thereof?                      Yes  [ ]   No  [x]

     If  so,  attach  an  explanation  of  the  anticipated  change,   both
     narratively and quantitatively, and, if appropriate, state the reasons
     why a reasonable estimate of the results cannot be made.


                         IGENE BIOTECHNOLOGY, INC.
               ____________________________________________
               (Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned
hereunto duly authorized.


DATE:  April 1, 2009                 By:  /s/ EDWARD J. WEISBERGER
       _____________   				____________________________
                                              EDWARD J. WEISBERGER
                                              Chief Financial Officer